Últimas noticias sobre Nixxy (NASDAQ:NIXX) Bolsa

Nixxy

Recruiter.Com Group

Nixxy Inc is a hiring platform for the network of recruiters. It empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology.Recently, the Company acquired the license from GoLogiq, Inc. (GoLogiq), to operate its fintech technology (the GOLQ Technology) and sell products derived thereof, including its Createapp, Paylogiq, Gologiq, and Radix AI technology and products.. Its Recruiters On Demand provides businesses of all sizes access to virtual recruiters specialized by vertical industries to source, engage, and hire talent on an as-needed basis.

Nixxy Inc

Jefferies analyst Julien Dumoulin-Smith upgrades Southwest Gas Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) from Hold to Buy and raises the price target from $74 to $82.

News

Upgrades

Price Target

Analyst Ratings

Jefferies Upgrades Southwest Gas Hldgs to Buy, Raises Price Target to $82

Jefferies analyst James Wheatcroft reinstates Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy and announces $380 price target.

Initiation

FLUT

Jefferies Reinstates Buy on Flutter Entertainment, Announces $380 Price Target

Looking ahead to 2026, Soligenix is positioning itself for a pivotal year marked by key clinical milestones and potential catalysts across its rare disease pipeline. Most notably, the company anticipates releasing top-line results from its confirmatory Phase 3 FLASH2 trial of HyBryte&#x2122; for early-stage cutaneous T-cell lymphoma in the second half of the year. With enrollment on track and prior data showing promising efficacy and safety, the outcome of FLASH2 could be transformational for HyBryte's regulatory and commercial trajectory. Soligenix is also actively exploring strategic partnerships and M&amp;A opportunities to maximize value creation, while targeting global marketing authorizations. Backed by a diversified pipeline, solid early clinical data, and an expanding manufacturing footprint, the company sees 2026 as a potential inflection point in its mission to deliver impactful therapies for underserved patient populations.
&nbsp;
&nbsp;

SNGX

Soligenix Issues Corporate Update Highlighting FLASH2 Phase 3 Progress, Psoriasis and Behçet's Trial Milestones, and Strategic Outlook Through 2026

ARWR

Arrowhead Pharmaceuticals Doses First Patient In Pivotal YOSEMITE Phase 3 Trial Of RNAi-Based Zodasiran For Homozygous Familial Hypercholesterolemia

WIIM

BCTX

BriaCell shares are trading higher after the company reported a 52% one-year survival rate in its Phase 2 metastatic breast cancer trial.

Jefferies analyst Surinder Thind downgrades WNS (Holdings) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) from Buy to Hold and lowers the price target from $80 to $76.5.

Downgrades

Jefferies Downgrades WNS (Holdings) to Hold, Lowers Price Target to $76.5

LakeShore Biopharma shares are trading higher after the company announced a $15 million private placement financing.

BriaCell Reports 52% One-Year Survival in Phase 2 Metastatic Breast Cancer Trial, Surpassing Standard of Care in Heavily Pre-Treated Patients

Financing

LakeShore Biopharma Enters $15M Share And Warrant Purchase Agreement With Institutional Investor

Martin Marietta  Appoints Michael J. Petro as Chief Financial Officer, Succeeding Interim CFO Robert J. Cardin Effective Immediately

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

SLNH

Soluna Holdings Announces 30 MW Expansion With A Bitcoin Miner At Dorothy 2 Site

NDRA: 156% &#x7C; <a href="https://www.benzinga.com/node/46285134">ENDRA Life Sciences shares are trading higher after the company announced it will be granted a US patent titled "Radio Frequency Applicator".</a>
&nbsp;
PROK: 158% &#x7C; <a href="https://www.benzinga.com/node/46292228">ProKidney shares are trading higher after the company reported statistically and clinically significant topline results from its Phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes.</a>
&nbsp;
LASE: 51% &#x7C; <a href="https://www.benzinga.com/node/46285555">Laser Photonics shares are trading higher after the company reported a year-over-year increase in Q1 revenue results.</a>

Movers

Trading Ideas

LASE

NDRA

PROK

Market-Moving News for July 8th

Colliers Securities analyst Barry Oxford initiates coverage on Bluerock Homes Trust (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BHM#AMEX">BHM</a>) with a Buy rating and announces Price Target of $15.

Bluerock Homes Trust, Inc. Class A Common Stock

Colliers Securities Initiates Coverage On Bluerock Homes Trust with Buy Rating, Announces Price Target of $15

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $50 price target.

Reiteration

URGN

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $50 Price Target

Biotech

General

PSTV

Plus Therapeutics Announces Treatment Of Initial Patients In ReSPECT-LM Dose Optimization Trial Of REYOBIQ In Leptomeningeal Metastases

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) reported a sharp rise in <a target="_blank" href="https://www.benzinga.com/topic/alibaba" rel="noreferrer noopener">on-demand delivery transactions</a>, with combined daily orders on its platforms, Taobao Instant Commerce and Ele.me, reaching 80 million. This information was shared in a Monday post on Alibaba&#8217;s official WeChat account, <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3317275/taobaos-daily-demand-orders-soar-chinas-instant-e-commerce-war-heats" rel="noreferrer noopener">as</a> reported by the South China Morning Post.
Taobao Instant Commerce, launched in late April, gained traction quickly. It hit 10 million daily orders in its first week and 40 million within a month, then jumped from 60 to 80 million in just 12 days amid summer promotions and subsidies.
The platform&#8217;s daily active users have now surpassed 200 million, signaling Alibaba&#8217;s intensified efforts to compete with rivals like Meituan (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGF#OTC">MPNGF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGY#OTC">MPNGY</a>) and JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) in the rapidly expanding instant delivery market.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/46091793/chinas-food-delivery-war-heats-up-as-jd-com-recruits-thousands-of-full-time-riders" rel="noreferrer noopener">China&#8217;s Food Delivery War Heats Up As JD.com Recruits Thousands Of Full-Time Riders</a>
In the ongoing competition, Meituan, a major player in the food delivery sector, reported 120 million daily transactions on Saturday, leading to brief server overloads as food and retail order volumes peaked during high-demand periods. Meituan maintains a steady hold on its 70% market share in domestic food delivery.
Alibaba&#8217;s strategic push into on-demand delivery is further evidenced by its commitment of a 50 billion yuan (approximately $7 billion) subsidy program for consumers and merchants over the next year. This program is designed to accelerate growth beyond Alibaba&#8217;s traditional e-commerce business.
To streamline operations and enhance its competitive edge against Meituan and JD.com, Alibaba integrated Ele.me and Fliggy into its <a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/46047699/alibaba-integrates-ele-me-and-fliggy-into-core-business-to-battle-rivals-in-delivery-war" rel="noreferrer noopener">core e-commerce unit</a> in June.
Analysts from Jefferies told the SCMP that Alibaba now focuses on integrating food delivery, instant commerce, and traditional retail to maximize synergies across segments.
Alibaba stated that the rapid expansion of Taobao Instant Commerce has contributed to a doubling of China&#8217;s total daily instant delivery orders across different platforms from around 100 million in May to 200 million.
Investors have shown optimism, pushing Alibaba and other Chinese stocks higher on Tuesday, largely in anticipation of the upcoming U.S. tariff deadline.
According to a report from Elara <a target="_blank" href="https://www.cnbctv18.com/market/stocks/global-investors-are-flocking-to-chinese-stocks-ahead-of-us-tariffs-deadline-19632525.htm" rel="noreferrer noopener">cited</a> by CNBC, Chinese equities saw $2.4 billion in inflows last week alone. This trend is part of a larger pattern, with emerging market funds attracting over $6 billion in the past three weeks, marking the fastest inflow pace since January 2023.
President Donald Trump had initially set a July 9 deadline for various countries to finalize trade deals to avoid higher tariff rates. However, the White House confirmed that President Trump will sign an executive order to delay this deadline to August 1, 2025. This three-week reprieve is intended to allow more time for trade negotiations, as the administration aims to secure favorable trade deals.
Price Action:&nbsp;BABA shares are trading higher by&nbsp;2.40% to&nbsp;$108.82 premarket at&nbsp;last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46250853/alibabas-ai-and-cloud-moves-have-sparked-28-stock-rebound" target="_blank" rel="noreferrer noopener">Alibaba&#8217;s AI And Cloud Moves Have Sparked 28% Stock Rebound</a></li>
</ul>
Photo by Robert Way via Shutterstock

Asia

Tech

Media

BABA

MPNGF

MPNGY

Alibaba's Delivery Ambition Sets Stage For China's Epic Clash Of Giants

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and maintains $75 price target.

LEGN

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $75 Price Target

MBAV

Trading Halt: Halted at 7:27:20 a.m. ET - Trading Halt: Halt News Pending

MBAVW

MBAVU

Press Releases

Nixxy Expands AI Portfolio with Purchase of Wizco's "Ava," an AI-Powered Interview Coaching Platform

Nixxy's Revenues Commence via Auralink AI

Nixxy Purchases CallAI and AQUA Health Coach Platforms for $3.9 Million in Cash and Stock

Nixxy Issues Operational Milestone Update and Highlights AI Integration Progress

Nixxy Appoints AI and MedTech Pioneer Ashissh Raichura to Board of Directors to Advance Secure, Compliant AI Infrastructure

Nixxy Announces Preliminary $1.4 Million in April Revenue; Executive Appointments to Strengthen Telecom Strategy

Management

Nixxy Appoints Mike Schmidt as CEO to Lead Telecom and AI Growth

Earnings

Nixxy Reports Over $1.39M in Q1 Revenue Following Strategic Pivot to AI Communications Infrastructure

Nixxy, Inc. Announces Acquisition of Leadnova.ai Platform Assets from NexGenAI and Reports $5.2 Million in May Revenue

Comments

Nixxy

Noticias

Últimas noticias sobre Nixxy (NASDAQ:NIXX) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL